The project, rolled out through Boehringer Ingelheim’s diabetes alliance with pharmaceutical company Eli Lilly and Co., will develop a risk model to predict the likelihood of three health outcomes associated with Type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure.
The researchers will develop the model using de-identified data from Geisinger’s EHR. The ultimate goal is to create a model that informs personalized treatments for patients with Type 2 diabetes.
“We hope the knowledge gained from this predictive model can help healthcare providers better target their treatment recommendations for people with Type 2 diabetes and, as a result, lower their risk for these serious diabetes-related consequences,” said Brent Williams, PhD, a research investigator at the Geisinger Center for Health Research.
More articles on data analytics & precision medicine:
8 things to know about gene-editing tech CRISPR
Louisiana State U, Moffitt Cancer Center partner to address racial disparities in precision medicine
Survey: Healthcare execs name data analytics, population health among top challenges for 2018
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
